Fig. 8: Comparison of BCar with clinical anti-mitotic drugs docetaxel (DOC) and vincristine (VIN) for the effect on the viability of human normal mammary epithelial cells and breast cancer cells. | Cell Death Discovery

Fig. 8: Comparison of BCar with clinical anti-mitotic drugs docetaxel (DOC) and vincristine (VIN) for the effect on the viability of human normal mammary epithelial cells and breast cancer cells.

From: Benzimidazole carbamate induces cytotoxicity in breast cancer cells via two distinct cell death mechanisms

Fig. 8

Cells were incubated with 0.5 µM BCar, DOC, or VIN for 24 h, exposed to 5 Gy radiation, and incubated for an additional 24 h. Cells were then washed and incubated for additional 7–14 days and analyzed for viability. A Representative samples from the cell viability assay. B Samples were quantified for cell survival using the ImageJ software. Results are expressed as mean ± s.d. of two sets of experiments in duplicate samples. C The EC50 of BCar among the breast normal and malignant cell lines were compared using an unpaired t-test. The P values showing significance (<0.05) from the comparisons are bolded.

Back to article page